Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C Clinical research trials and Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C. Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C clinical trial. Test subjects typically obtain the finest healthcare available for their Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C

Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C



Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C

For Condition: Hepatitis C
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , Tulane University School of Medicine
Synopsis: OBJECTIVES: I. Determine whether the initial response to interferon alfa (IFN-A) can be increased by starting at a dose of 5 MU three times a week in patients with chronic hepatitis C. II. Determine whether patients who had normalized alanine aminotransferase (ALT) levels can maintain normal ALT during stepwise dose reduction from 5 MU to 3 MU to 1.5 MU.
Details: PROTOCOL OUTLINE: Patients are randomly assigned to 1 of 2 treatment groups in a 2:1 ratio. The first group is treated with high-dose interferon alfa (IFN-A) administered subcutaneously twice a week for 12 weeks. If the alanine aminotransferase (ALT) level has normalized, the IFN-A dose is decreased in a stepwise fashion. If the ALT level decreases by more than 50%, IFN-A is continued at the same dose until week 24 or the ALT normalizes. If the ALT level decreases by less than 50%, treatment is discontinued. The second group is treated with standard-dose IFN-A administered subcutaneously twice a week for 24 weeks.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Biopsy-proven chronic hepatitis Anti-hepatitis C virus positive Hepatitis B surface antigen negative - No decompensated cirrhosis --Prior/Concurrent Therapy-- - No concurrent immunosuppressives At least 1 year since interferon --Patient Characteristics-- - Hepatic: No other cause of liver disease - Other: Not HIV positive
Total Enrollment: 57

Location and Contact Information:

Overall Study Official:
AnnaF. Lok,  Study Chair,  Tulane University School of Medicine


Additional Information:
Study ID Numbers:  199/11964;  TUMC-M1260
Study Start Date: August 1993
Record last reviewed: February 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004804

Other Hepatitis C Studies:
1. Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

2. Thymosin Plus PEG-Interferon in Hepatitis C Patients with Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

3. Treatment of Cholestatic Pruritus With Sertraline

4. Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

5. The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon alpha-2b and Ribavirin

Related Studies:

Other Hepatitis C Clinical Trials
Other Clinical Trials
Other Clinical Trials

Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C
Modify your Search

  Other Hepatitis C Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103